David Novak

Stock Analyst at Raymond James

(0.57)

# 4,077

Out of 5,182 analysts

7

Total ratings

42.86%

Success rate

-13.85%

Average return

Main Sectors:

Top Industries:

Stocks Rated by David Novak

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	ZYME Zymeworks	Downgrades: Outperform	$74	$27.94	+164.85%	6	Dec 10, 2021
	CBIO Crescent Biopharma	Maintains: Outperform	$300 → $270	$23.96	+1,026.88%	1	Feb 4, 2021

Zymeworks

Dec 10, 2021

Downgrades: Outperform

Price Target: $74

Current: $27.94

Upside: +164.85%

Crescent Biopharma

Feb 4, 2021

Maintains: Outperform

Price Target: $300 → $270

Current: $23.96

Upside: +1,026.88%